The Ma'ayan Laboratory leads the Mount Sinai Knowledgement Center for Illuminating the Druggable Genome (IDG). Our leading achievement during the pilot phase of IDG was the development, deployment, and publication of the Harmonizome resource. The Harmonizome resource epitomizes the IDG concept because its gene/protein landing pages illuminate knowledge about all human genes and proteins, including those under-studied potential targets.
The goal of this project is to collect, process, and serve attributes about druggable targets from four protein families: protein kinases, G-protein coupled receptors, nuclear receptors, and ion channels. We focus on genes and proteins that have not been studied extensively but have the potential to become useful drug targets.
We also collect, process, and serve data for all other mammalian genes and proteins; drugs small molecules, and other perturbagens; pheontypes, diseases, and side effects; and clinical genomics datasets from cohorts of patients. These processed data enable us to identify links between and across these various sources of information, and to encourage new discoveries. We develop and apply clustering and classification algorithms as well as workflow analyses to help predict the applicability of targeting these under-studied proteins for translational applications in personalized medicine.
Learn more about the grant
Visit the Harmonizome, a web-based system that serves all the data processed for this project